Can You Take Evenity (Romosozumab) with Trazodone?

Why This Combination Comes Up in Practice

Osteoporosis patients prescribed romosozumab frequently take trazodone for insomnia or depression. In the FRAME trial (N=7,180), the median participant age was 70.9 years [1]. Sleep disturbance affects 36% to 58% of postmenopausal women according to a 2017 meta-analysis published in Sleep Medicine Reviews [2]. Trazodone remains one of the most commonly prescribed off-label sleep aids in older adults, with over 25 million U.S. prescriptions annually in the 65-plus population [3].

Clinicians face a practical question: does adding a monthly sclerostin inhibitor to a patient already on nightly trazodone create a safety signal? The short answer is no direct drug-drug interaction exists. But the indirect risk, specifically fall-related fractures in a population already identified as high-fracture-risk, deserves structured attention.

Pharmacokinetic Analysis: No Metabolic Overlap

Romosozumab is a humanized IgG2 monoclonal antibody. Its elimination follows the same pathway as endogenous immunoglobulins: intracellular proteolysis via the reticuloendothelial system and target-mediated disposition through sclerostin binding [4]. It does not undergo Phase I oxidation, Phase II conjugation, or renal tubular secretion. The FDA prescribing information for Evenity explicitly states that "no formal drug interaction studies have been conducted" because monoclonal antibodies "are not expected to be metabolized by cytochrome P450 enzymes" [4].

Trazodone, by contrast, is extensively metabolized by CYP3A4, with minor contributions from CYP2D6 [5]. Its primary active metabolite, meta-chlorophenylpiperazine (mCPP), is formed via CYP3A4-mediated N-dealkylation. Strong CYP3A4 inhibitors (ritonavir, ketoconazole) increase trazodone AUC substantially. Strong inducers (carbamazepine, phenytoin) decrease it.

Because romosozumab has zero CYP activity, zero P-gp modulation, and zero plasma protein binding competition at the small-molecule level, it cannot alter trazodone concentrations. The reverse is equally true: trazodone cannot affect monoclonal antibody clearance, which is governed by FcRn recycling and target antigen density rather than hepatic enzyme activity.

The Real Concern: Pharmacodynamic Sedation and Fall Risk

The absence of a pharmacokinetic interaction does not mean this combination is risk-free. The clinical concern is pharmacodynamic: additive CNS depression leading to falls.

Trazodone produces dose-dependent sedation through antagonism at histamine H1 receptors and serotonin 5-HT2A receptors [5]. At hypnotic doses (25 to 100 mg), next-morning residual sedation is common in older adults due to age-related reductions in hepatic blood flow and CYP3A4 activity. A 2020 retrospective cohort study in Journal of Clinical Sleep Medicine found that trazodone use in adults over 65 was associated with a 1.34-fold increased risk of hip fracture (95% CI 1.10 to 1.63) [6].

Romosozumab itself carries labeling for arthralgia (12.4% vs. 10.6% placebo in FRAME) and headache, and the ARCH trial (N=4,093) showed a cardiovascular safety signal that led to a boxed warning [7]. While romosozumab does not cause sedation directly, injection-site reactions and transient malaise on dosing days could compound trazodone's sedative effects during the first 24 to 48 hours post-injection.

The Endocrine Society's 2020 clinical practice guideline on osteoporosis management recommends fall-risk assessment as a co-intervention alongside any pharmacologic osteoporosis therapy [8]. This recommendation carries particular weight when the patient's medication list includes a known sedating agent.

Severity Classification Across DDI Databases

Major drug interaction databases classify this combination consistently:

The Lexicomp database rates romosozumab-trazodone as having no listed interaction, reflecting the absence of pharmacokinetic overlap. Clinical Pharmacology (Elsevier) similarly shows no monograph-level interaction. The Beers Criteria from the American Geriatrics Society does not address this specific pair but flags trazodone independently as potentially inappropriate in older adults due to sedation, orthostatic hypotension, and fall risk [9].

This classification gap matters. A prescriber checking only for "interactions" in their EHR may receive a green light, missing the pharmacodynamic fall-risk amplification that exists at the patient level. The interaction is not between the molecules. It is between the drug effects and the patient's baseline fragility.

Monitoring Protocol for Co-Prescribed Patients

Dr. Felicia Cosman, writing in the Journal of Bone and Mineral Research, noted that "the greatest threat to patients on anabolic osteoporosis therapy is a fall that occurs before the drug has time to rebuild cortical bone density" [10]. Romosozumab achieves peak BMD gains at month 12, meaning the first several months of therapy represent a window of vulnerability.

A structured monitoring approach for patients on both drugs includes:

At baseline (before first romosozumab injection): Document trazodone dose, timing, and duration. Perform Timed Up and Go (TUG) test. Record any prior falls in the preceding 12 months. Check orthostatic blood pressure.

At each monthly injection visit: Ask specifically about nocturnal falls, morning dizziness, and bathroom-related instability. Reassess if trazodone dose has been changed by another provider. The monthly visit cadence of romosozumab creates a natural monitoring interval that many other osteoporosis regimens lack.

At month 6: Repeat TUG. Consider whether trazodone can be tapered if sleep architecture has improved or if cognitive behavioral therapy for insomnia (CBT-I) has been initiated. The American Academy of Sleep Medicine recommends CBT-I as first-line treatment for chronic insomnia, noting that it eliminates sedative-hypnotic fall risk entirely [11].

Dose Adjustment: Not Required, But Context Matters

No dose reduction of either drug is warranted based on co-administration alone. Romosozumab is given as a fixed 210 mg dose (two 105 mg subcutaneous injections) with no titration or weight-based adjustment [4]. Trazodone dosing for insomnia typically ranges from 25 to 100 mg at bedtime, and for depression from 150 to 400 mg daily in divided doses.

However, if a patient reports new-onset daytime somnolence, unsteadiness, or a near-fall after starting romosozumab, the appropriate response is not to reduce the romosozumab dose. Instead, re-evaluate trazodone timing and dose. Shifting trazodone administration earlier in the evening (9 PM rather than 11 PM for a patient who rises at 6 AM) can reduce residual morning sedation. Dose reduction from 100 mg to 50 mg maintains hypnotic efficacy for most older adults while reducing next-day impairment [5].

Special Populations: Renal Impairment and Polypharmacy

Romosozumab pharmacokinetics are not altered by renal impairment because monoclonal antibodies are too large (149 kDa) for glomerular filtration [4]. Trazodone's renal excretion of parent compound is minimal (<1%), but mCPP clearance decreases in moderate-to-severe renal impairment, potentially increasing sedation duration [5].

In patients with eGFR <30 mL/min/1.73m², trazodone's sedative effects may be prolonged. Combined with the cardiovascular boxed warning on romosozumab (which contraindicates use in patients with MI or stroke within the preceding year), this subgroup requires careful benefit-risk assessment [7].

Polypharmacy amplifies the concern. A patient taking trazodone, an alpha-blocker for BPH, and a thiazide diuretic already has three contributors to orthostatic hypotension. Adding romosozumab does not worsen orthostasis pharmacologically, but the clinical logic remains: this patient's skeleton is fragile enough to warrant an anabolic agent, which means any fall carries disproportionate fracture consequence.

Cardiovascular Considerations

The ARCH trial compared romosozumab to alendronate and identified a higher rate of adjudicated serious cardiovascular events (2.5% vs. 1.9%) in the romosozumab arm over 12 months [7]. Trazodone can prolong the QTc interval modestly, with a mean increase of approximately 5 to 10 ms at therapeutic doses based on thorough QT study data in the FDA review [5].

These are independent signals. No evidence suggests romosozumab potentiates trazodone's cardiac effects or vice versa. The FDA label for Evenity does not list QTc prolongation as a risk. Still, in a patient with baseline QTc >470 ms or concurrent use of other QTc-prolonging agents, an ECG at baseline before initiating both drugs represents reasonable clinical caution.

Patient Counseling Points

Patients receiving both medications should be told:

These two drugs do not interact in the traditional sense. Your body processes them through completely separate pathways. The concern is practical, not chemical: trazodone can make you drowsy, and drowsiness increases fall risk. Falls are exactly what we are trying to prevent while Evenity strengthens your bones.

Take trazodone only at bedtime, in bed, with the lights already off. Do not take it and then walk around the house. If you need to use the bathroom at night, sit on the edge of the bed for 30 seconds before standing. Use nightlights along your path. These are not optional suggestions; they are part of your treatment plan.

Report any dizziness, near-falls, or actual falls at your next monthly injection visit. We may adjust your trazodone dose or timing based on what you tell us.

When to Involve a Specialist

Referral to a geriatrician or falls-prevention clinic is appropriate when a patient on this combination has experienced two or more falls in six months, has a TUG score exceeding 12 seconds, or is taking four or more CNS-active medications concurrently. The Stopping Elderly Accidents, Deaths & Injuries (STEADI) algorithm from the CDC provides a validated framework for this triage decision [12].

A bone-metabolism specialist (endocrinologist) should be involved if the prescriber is considering early discontinuation of romosozumab due to fall events, since premature cessation wastes the anabolic window and necessitates immediate transition to an antiresorptive to prevent bone loss rebound [8].

Romosozumab's 12-month treatment course means the co-prescription period is finite. After completing the romosozumab course, patients typically transition to denosumab or a bisphosphonate. The fall-risk monitoring should continue, but the urgency of preserving the anabolic treatment window resolves.